pT3或pT4期肝细胞癌肝切除与序贯经动脉化疗栓塞术的比较
[Comparison of liver resection with sequential transarterial chemoembolization in stage pT3 or pT4 hepatocellular carcinoma].
作者信息
Hasse F, Mehring U M, Castaneda F, Jäger H, Mathias K D, Löhlein D
机构信息
Chirurgische Klinik, Städtische Kliniken Dortmund.
出版信息
Langenbecks Arch Chir Suppl Kongressbd. 1996;113:208-10.
Between January 1990 and January 1996, 39 consecutive patients with histologically improved pT3 or pT4 HCC tumors underwent curative resection (n = 19) or sequential transarterial chemoembolization (n = 20) with a median time interval of 7 weeks up to six times with an emulsion of Lipiodol, Epirubicin and Cisplatin. The 30-day mortality rate for all sessions of TA was 3.8% vs. 21.8% in the resection group (p < 0.05); the cumulative survival rate for the embolization group at 6, 12, 18 and 24 months was 72.3%, 50.1%, 41.2%, 35.4% vs. 42.1%, 31.6%, 31.6% and 14.2% following resection, which cannot be considered statistically significant. Patients with T3 and T4 HCC, treated with sequential embolization or resection, seem to have a comparable survival time.
1990年1月至1996年1月期间，39例组织学检查显示pT3或pT4期肝癌肿瘤有所改善的患者接受了根治性切除术（n = 19）或序贯经动脉化疗栓塞术（n = 20），中位时间间隔为7周，最多进行6次，使用碘油、表柔比星和顺铂乳剂。经动脉化疗栓塞术所有疗程的30天死亡率为3.8%，而切除组为21.8%（p < 0.05）；栓塞组在6、12、18和24个月时的累积生存率分别为72.3%、50.1%、41.2%、35.4%，而切除术后分别为42.1%、31.6%、31.6%和14.2%，差异无统计学意义。接受序贯栓塞或切除治疗的T3和T4期肝癌患者的生存时间似乎相当。
Zotero 插件